You are here

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male and Female patients 18 to 65 y/old

- Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled
BP

- Patient with uncontrolled mild to moderate hypertension (SBP>= 140 and DBP of >=90 and

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnant of Lactating women

- History of secondary hypertension

NCT00796159
Pfizer
Completed
Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Pulmonary Arterial Hypertension
NCT01897740
All Genders
10+
Years
Moscow,
Pulmonary Arterial Hypertension
NCT02060487
All Genders
18+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT03364244
All Genders
0+
Years
Tokyo,
Pulmonary Arterial Hypertension
NCT00878943
All Genders
18+
Years
Multiple Sites
Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide
A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertension
This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension
Non Probability Sampling
Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
Filipino patients with Uncontrolled Mild to Moderate Essential Hypertension
Hypertension
Drug: Olmesartan medoxomil
olmesartan medoxomil 20 mg and HCTZ 12.5 mg
Olmesartan medoxomil + HCTZ
Intervention: Drug: Olmesartan medoxomil
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1723
December 2008
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and Female patients 18 to 65 y/old
  • Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled BP
  • Patient with uncontrolled mild to moderate hypertension (SBP>= 140 and <=179 mmHg OR DBP of >=90 and <=109 mmHg)

Exclusion Criteria:

  • Pregnant of Lactating women
  • History of secondary hypertension
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00796159
A0021004
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2009

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now